ICOS and neoplasm: A first approach was to develop agonist mAbs targeting ICOS that activate this signaling and exert anti-tumor activity by co-stimulating low ICOS+ Teff cells, thereby promoting activation and expansion of Teff cells, which in turn increase cytotoxic activity against tumor cells.